Loading organizations...
§ Private Profile · Kingston
Pharmaceutical company developing immune-targeted CNS disease treatments.
MindImmune Therapeutics develops novel immunomodulatory therapeutics aimed at addressing neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's lead therapeutic candidate, MITI-101, is a first-in-class monoclonal antibody designed to prevent specific immune cells from entering the brain. This approach seeks to halt neuro-inflammation, preserve neuronal connections, and ultimately protect brain health by redirecting the immune system's activity.
The company was founded in 2016 by Stevin Zorn, Ph.D., Frank Menniti, Ph.D., and Robert Nelson, Ph.D., who initially collaborated as scientific colleagues. MindImmune originated from the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island. Their foundational insight centered on identifying a peripheral innate immune cell that, upon entering the brain, drives neuro-inflammation and contributes to the destruction of neural connections in neurodegenerative conditions.
MindImmune Therapeutics targets individuals afflicted with or at risk of neurodegenerative disorders, particularly Alzheimer's disease. The company's overarching vision is to prevent the progression of neuroinflammatory diseases and safeguard long-term brain health. By intervening in the immune system's detrimental role, MindImmune aims to provide a novel therapeutic pathway to address these debilitating conditions.
MindImmune Therapeutics has raised $27.2M across 3 funding rounds.
MindImmune Therapeutics has raised $27.2M in total across 3 funding rounds.
MindImmune Therapeutics has raised $27.2M in total across 3 funding rounds.
MindImmune Therapeutics's investors include Howard Fillit, Reetika Bhardwaj, Foundation for a Better World, Gates Frontier, RightHill Ventures, Slater Technology Fund, Dolby Family Ventures, SR One, Heather Preston.
MindImmune Therapeutics has raised $27.2M across 3 funding rounds. Most recently, it raised $5.0M Other Equity in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 10, 2026 | $5M Venture Round | Howard Fillit | — | Announced |
| Nov 24, 2025 | $10.2M Series A Plus | Reetika Bhardwaj | Foundation For A Better World, Gates Frontier, Righthill Ventures, Slater Technology Fund | Announced |
| Jun 1, 2022 | $12M Series A | — | Dolby Family Ventures, SR ONE, Heather Preston | Announced |
MindImmune Therapeutics is a biotechnology company focused on developing novel therapeutics for neurodegenerative diseases, primarily Alzheimer's disease, by targeting neuroinflammation through immune system modulation. Their lead product is MITI-101, a first-in-class monoclonal antibody designed to prevent harmful innate immune cells from entering the brain, thereby halting synaptic damage that leads to cognitive decline. The company serves patients with Alzheimer's and related CNS disorders, addressing the critical problem of immune-driven neurodegeneration. Founded in 2016, MindImmune has demonstrated promising preclinical progress and secured significant funding, including a $12.4 million Series A round, signaling strong growth momentum in the neurotherapeutics space[1][2][3].
MindImmune was founded by a team of experienced CNS researchers—Stevin Zorn, Frank Menniti, and Robert Nelson—who previously collaborated at Pfizer’s Worldwide Research & Development. The idea emerged from their recognition of the immune system’s role in brain diseases and the discovery of a novel therapeutic target: innate immune cells recruited from the blood into the brain that cause synaptic damage in Alzheimer's. Early pivotal moments included two "Eureka" discoveries enabled by advanced instrumentation at the University of Rhode Island’s RI-INBRE center, which helped identify and validate this immune cell recruitment mechanism. The company maintains a close collaboration with the Ryan Institute for Neuroscience at URI, fostering a strong public-private research partnership[1][3].
MindImmune is positioned at the forefront of a growing trend to harness the immune system for treating neurodegenerative diseases, a shift from conventional approaches focused solely on neuronal targets. The timing is critical as neuroinflammation is increasingly recognized as a key driver of Alzheimer's pathology, and there is a pressing need for innovative therapies beyond amyloid and tau. Market forces favor companies that can offer novel mechanisms of action with potential for disease modification. MindImmune’s work contributes to expanding the therapeutic landscape for CNS disorders and exemplifies the integration of immunology and neuroscience, influencing both academic research and pharmaceutical development paradigms[1][4][6].
Looking ahead, MindImmune is expected to advance MITI-101 through clinical development, potentially expanding its pipeline to other neurodegenerative and chronic inflammatory diseases driven by immune dysfunction. Trends such as precision medicine, biomarker-driven diagnostics, and immune modulation will shape their journey. Their ability to measure immune cell recruitment as a biomarker could enhance patient stratification and therapeutic monitoring, increasing the impact of their treatments. As the field embraces immune-based therapies for brain diseases, MindImmune’s innovative platform and strong scientific foundation position it to be a significant player in transforming neurodegenerative disease treatment[6][4].
MindImmune Therapeutics exemplifies a cutting-edge biotech venture that leverages deep scientific insight and collaborative innovation to address one of the most challenging medical conditions of our time—Alzheimer’s disease—by "nipping it in the blood" through immune system redirection.